Free Trial
NASDAQ:LEXX

Lexaria Bioscience (LEXX) Stock Price, News & Analysis

Lexaria Bioscience logo
$0.83 -0.01 (-1.07%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$0.83 0.00 (-0.48%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lexaria Bioscience Stock (NASDAQ:LEXX)

Key Stats

Today's Range
$0.82
$0.85
50-Day Range
$0.81
$1.05
52-Week Range
$0.79
$4.38
Volume
117,397 shs
Average Volume
205,362 shs
Market Capitalization
$16.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Lexaria Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

LEXX MarketRank™: 

Lexaria Bioscience scored higher than 53% of companies evaluated by MarketBeat, and ranked 423rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lexaria Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lexaria Bioscience has only been the subject of 1 research reports in the past 90 days.

  • Read more about Lexaria Bioscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Lexaria Bioscience are expected to grow in the coming year, from ($0.59) to ($0.46) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lexaria Bioscience is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lexaria Bioscience is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lexaria Bioscience has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.92% of the float of Lexaria Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexaria Bioscience has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Lexaria Bioscience has recently increased by 1.90%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Lexaria Bioscience does not currently pay a dividend.

  • Dividend Growth

    Lexaria Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.92% of the float of Lexaria Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexaria Bioscience has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Lexaria Bioscience has recently increased by 1.90%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Lexaria Bioscience has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Lexaria Bioscience this week, compared to 0 articles on an average week.
  • Search Interest

    Only 1 people have searched for LEXX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Lexaria Bioscience to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lexaria Bioscience insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,063.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    26.40% of the stock of Lexaria Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 13.06% of the stock of Lexaria Bioscience is held by institutions.

  • Read more about Lexaria Bioscience's insider trading history.
Receive LEXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.

LEXX Stock News Headlines

HC Wainwright Expects Lower Earnings for Lexaria Bioscience
Crypto bros: Meet your replacement
Larry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities.
LEXX: Third Quarter Results
LEXX - Lexaria Bioscience Corp Dividends - Morningstar
See More Headlines

LEXX Stock Analysis - Frequently Asked Questions

Lexaria Bioscience's stock was trading at $2.10 on January 1st, 2025. Since then, LEXX shares have decreased by 60.5% and is now trading at $0.83.

Lexaria Bioscience Corp. (NASDAQ:LEXX) released its earnings results on Monday, July, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.06. The business had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.17 million. Lexaria Bioscience had a negative net margin of 1,849.19% and a negative trailing twelve-month return on equity of 157.22%.

Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and Builders FirstSource (BLDR).

Company Calendar

Last Earnings
7/14/2025
Today
8/08/2025
Fiscal Year End
8/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LEXX
CIK
1348362
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

High Price Target
$4.00
Low Price Target
$4.00
Potential Upside/Downside
+381.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.80 million
Net Margins
-1,849.19%
Pretax Margin
-1,850.97%
Return on Equity
-157.22%
Return on Assets
-133.69%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.90
Quick Ratio
3.90

Sales & Book Value

Annual Sales
$460 thousand
Price / Sales
35.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.48 per share
Price / Book
1.73

Miscellaneous

Outstanding Shares
19,560,000
Free Float
14,395,000
Market Cap
$16.23 million
Optionable
Not Optionable
Beta
0.79
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:LEXX) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners